Abbott's board announced a quarterly dividend of 63 cents per share, marking the company's 410th consecutive quarterly dividend since 1924. This consistent dividend payment underscores Abbott's long-standing commitment to returning value to shareholders. The dividend will be paid on August 17, 2026, to shareholders recorded by July 15, 2026. Abbott has increased its dividend payout for 54 consecutive years and is part of the S&P 500 Dividend Aristocrats Index, highlighting its stability and reliability as an investment.
Abbott Laboratories (ABT) is positioned for multi-pronged growth driven by its diagnostics, nutrition, and medtech segments, with management targeting a 7% organic growth rate. The recent acquisition of EXAS adds some balance sheet and bottom-line ri...
Abbott Laboratories has seen a strong rally since May, supported by growth in its core Medical Devices segment and the recent acquisition of Exact Sciences. The company holds an A+ credit rating with a stable outlook, and its shares currently trade a...
Abbott Laboratories reported strong Q2 earnings that exceeded expectations, driving its stock up 14%. The company also raised its full-year 2026 guidance, signaling confidence in future growth. Key business areas like diagnostics and electrophysiolog...
UK GDP grew 0.8% over three months, surpassing forecasts and showing resilience despite geopolitical tensions and energy price pressures. The FTSE 100 opened lower as investors digested takeover deals including Rotork's £4.1bn acquisition by ABB and ...
Abbott posted a 13% increase in reported sales and 4.8% comparable sales growth for Q2 2026, with GAAP diluted EPS at $0.53 and adjusted EPS at $1.31. The company reaffirmed its full-year 2026 sales growth guidance of 6.5% to 7.5% and raised its adju...
